TABLE 2

Characteristics of study subjects

Case numberAge (years)SexDiabetes duration (days)HLA DRB1GAD Ab* (arbitrary units)IA-2 Ab (arbitrary units)Insulin autoantibodies (arbitrary units)Islet cell Abs (Juvenile Diabetes Foundation units)§
HLA-A2+ type 1 diabetic patients (n = 22)
P0117M1221,9391,5293.77Negative
P0238M18004–162,817132.54640
P0337M6007–082,89829.90.24
P0443M511–1560110.30Negative
P0536F603–083,848191.04
P0621F2403–162,8945980.40
P0733M801–0395130.2720
P0823M1604–1358180.315
P0932M292,792130.28Negative
P1033M192,1145050.44
P1116F601–011,4415780.2920
P1219M2003–03283150.34Negative
P1325M301–032,970
P1428M403–043,1252,4390.86
P1518M1303–15883110.35
P1629M2603–042,5481,5700.3520
P1727M7003–133,292300.77Negative
P1836M504–1358150.35Negative
P1946F1101–033,1921330.27
P2024F403–131,6022,8760.33
P2136F404–041262,0391.00
P2226M303–1028210.30Negative
HLA-A2+ healthy subjects (n = 22)
C0125F13–1440190.23Negative
C0226F09–1137110.20Negative
C0330F01–1641150.37Negative
C0432M11–1660100.22Negative
C0555M03–13
C0626F07–0748160.40Negative
C0729M09–136350.21
C0833F04–146390.23Negative
C0927M07–1525160.26Negative
C1026F08–11
C1125F11–1548140.36Negative
C1223F03–1141260.76Negative
C1358F07–14
C1429F04–1146130.19Negative
C1527M01–1166280.20Negative
C1656F
C1726F01–0743270.28Negative
C1826F13–1570140.15
C1925M76200.28Negative
C2048F04–1170130.13
C2135M
C2233M60140.49
HLA-A2+ type 2 diabetic patients (n = 5)Therapy
Q0126M704–094825Insulin
Q0231M511–12466NegativeInsulin
Q0346M16211–16159NegativeOHA
Q0456M19204–161712NegativeOHA
Q0541M36011–116613NegativeOHA
HLA-A2 type 1 diabetic patients (n = 4)
N0142F293,7842,6880.30
N0241M181,1131,4050.22
N0315F604–04594190.42
N0419F1603–041,1752953.6680
  • The 97.5th percentile cutoff values for Ab titers are as follows:

  • *

    * GAD Abs: 180 arbitrary units.

  • IA-2 Abs: 80 arbitrary units.

  • Insulin autoantibodies: 0.7 arbitrary units.

  • §

    § Islet cell Abs: 5 Juvenile Diabetes Foundation units. Positive Ab titers are displayed in bold. —, Not done; OHA, oral hypoglycemic agent.